7 results match your criteria: "Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou[Affiliation]"
Conference 2024: Building an innovative scientific research ecosystem for microbiome and One Health.
Imeta
December 2024
Genome Analysis Laboratory of the Ministry of Agriculture and Rural Affairs, Agricultural Genomics Institute at Shenzhen Chinese Academy of Agricultural Sciences Shenzhen China.
The Conference 2024 provides a platform to promote the development of an innovative scientific research ecosystem for microbiome and One Health. The four key components - Technology, Research (Biology), Academic journals, and Social media - form a synergistic ecosystem. Advanced technologies drive biological research, which generates novel insights that are disseminated through academic journals.
View Article and Find Full Text PDFDiscovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer.
Mol Cancer
September 2024
State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research, Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou, Guangzhou, 510060, China.
Colitis-associated colorectal cancer (CAC) frequently develops in patients with inflammatory bowel disease (IBD) who have been exposed to a prolonged state of chronic inflammation. The investigation of pharmacological agents and their mechanisms to prevent precancerous lesions and inhibit their progression remains a significant focus and challenge in CAC research. Previous studies have demonstrated that vitexin effectively mitigates CAC, however, its precise mechanism of action warrants further exploration.
View Article and Find Full Text PDFArticle Synopsis
- A new study has developed a saliva biopsy method for detecting nasopharyngeal carcinoma (NPC), showing the potential of using oral samples for diagnosis.
- Researchers collected 907 samples, including saliva and swabs, and found significant increases in Epstein‒Barr virus (EBV) DNA methylation in NPC patients.
- The study suggests that using saliva and oropharyngeal swabs together can improve NPC detection and indicates the possibility of self-sampling for home-based screening.
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies.
Imeta
February 2024
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.
Article Synopsis
- Gut microbiota helps keep our immune system balanced, especially when fighting off bad bacteria!
- It plays a tricky role in cancer, affecting both how cancers grow and how well cancer treatments work!
- Scientists are exploring how changing the types of bacteria in our gut might make cancer treatments more effective or reduce side effects!
Interleukin-33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species-mediated inhibition of nuclear factor kappa-B signal and stemness properties.
MedComm (2020)
May 2024
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou PR China.
Article Synopsis
- Bortezomib (BTZ) is a key treatment for multiple myeloma (MM), but resistance to it limits its effectiveness.
- Interleukin-33 (IL-33) has potential antitumor effects and, when combined with BTZ, shows improved results in treating MM by enhancing immune responses and inducing cancer cell death.
- High levels of IL-33 in BTZ-treated patients are linked to better outcomes, as IL-33 boosts BTZ's effectiveness through mechanisms involving increased reactive oxygen species (ROS) and suppression of stemness-related gene expression.
Disruption of disulfide homeostasis during biological processes can have fatal consequences. Excess disulfides induce cell death in a novel manner, termed as "disulfidptosis." However, the specific mechanism of disulfidptosis has not yet been elucidated.
View Article and Find Full Text PDFBackground: The effect of pain genes (NAV1, EHMT2, SP1, SLC6A4, COMT, OPRM1, OPRD1, CYP2D6, and CYP3A4) have not been reported previously in kidney renal clear cell carcinoma (KIRC) patients and thus we made a comprehensive analysis of pain genes in the prognosis of KIRC and tumor immunotherapy.
Methods: In this study, TCGA, Kaplan-Meier plotter, Metascape, STRING, Human Protein Atlas, Single Cell Expression Atlas database, LinkedOmics, cBioPortal, MethSurv, CancerSEA, COSMIC database and R package (ggplot2, version 3.3.